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replacement therapy? Definitely … maybe
Patrick M. Honore*, Rita Jacobs, Inne Hendrickx, Elisabeth De Waele, Viola Van Gorp and Herbert D. SpapenSee related research by Schilder et al., http://www.ccforum.com/content/18/2/R78; and Vasileiadis et al., http://www.ccforum.com/content/19/1/140Two recent studies published in Critical Care reported
that plasma [1] and urinary [2] levels of neutrophil
gelatinase-associated lipocalin (NGAL), an important
biomarker for prediction and diagnosis of acute kidney
injury, were not affected by continuous renal replacement
therapy (CRRT).
The investigators assessed NGAL elimination during
continuous venovenous hemofiltration [1] and hemodia-
filtration [2] using respectively a cellulose triacetate [1]
and a polysulfone [2] membrane filter. Of note is that
these filters both have notoriously low adsorption cap-
acity [3]. Recently, the proinflammatory high-mobility
group box 1 protein, a cytokine with a molecular weight
approximating that of NGAL, was also found to be un-
affected by convective CRRT. However, it was significantly
(up to 90 %!) cleared from the circulation when highly
adsorptive membranes (i.e., surface-treated acrylonitrile
69 and polymethylmethacrylate) were used [4].
These membranes are increasingly applied for hemofil-
tration in critically ill patients [4]. Thus, it is imperative
to evaluate NGAL clearance during convective CRRT
performed with highly adsorptive membranes before
definitively accepting that CRRT leaves the sensitivity of
this biomarker intact.
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